Clinical Study of Cefprozil in Treatment of Respiratory Tract Infections

王明贵,张婴元,汪复,徐楠,梁德荣,郑丽叶,邓伟吾
DOI: https://doi.org/10.3969/j.issn.1007-7669.2002.06.008
2002-01-01
Abstract:AIM: To evaluate the efficacy and safety of domestic cefprozil tablet in the treatment of respiratory tract infections. METHODS: A total of one hundred and one patients with lower respiratory tract infections were randomly divided into two groups:cefprozil group fifty-one patients (M 33,F 18; age 50 a±s13 a) were treated with cefprozil 500 mg,po,bid, and cefaclor group fifty patients (M 29, F 21; age 49 a±15 a)were treated with cefaclor 500 mg, po, tid for 7-14 d. Fifty-five patients with upper respiratory tract infections in open group were treated with cefprozil 500 mg, po, qd for 7-14 d. RESULTS: In the randomized controlled study, the clinical efficacy rate of cefprozil and cefaclor was 94 %(48/51) and 92 %(46/50), respectively.The bacterial elimination rate was 93%(41/44 and 39/42) in both groups. The adverse reaction occurrence rate was 10 %(5/52) and 8 %(4/51), respectively. There was no statistically significant difference between the above data of two groups. The clinical effective rate and bacterial elimination rate of cefprozil in the treatment of upper respiratory tract infections was 94 %(52/55) and 90 %(44/49), respectively. The adverse reaction rate was 4 %(2/55). CONCLUSION: Cefprozil is effective and safe in the treatment of respiratory tract infections.
What problem does this paper attempt to address?